T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib
improves progression-free survival compared to single agent T-DM1in patients with metastatic
HER2 positive breast cancer